M&A News

Analysis

Ford's minority-retained structure limits upside but caps downside capital exposure in European EVs at a moment when legacy OEM EV profitability remains under pressure. By keeping majority control, Ford preserves the Almussafes asset on its balance sheet without a full write-down, while Geely's 34% stake funds a portion of retooling. The risk is that a multi-energy rather than pure-EV mandate blurs the venture's competitive positioning at a time when EU fleet CO2 targets require clear electrification commitments from 2035.

Analysis

AMD's 2.5% premarket decline despite a multi-tens-of-billions revenue commitment reveals that investors are discounting the revenue stream's timing and crediting the $5bn capital outlay immediately. The deal structure resembles a vendor financing arrangement where AMD funds a customer to buy its own chips, compressing near-term free cash flow. Combined with Intel's 11% earnings surge on AI data centre share gains, consensus models for AMD's data centre segment growth face a credibility problem on both the cost and the competitive side.

Analysis

Samsung Biologics' 207940.KS faces near-term capital structure scrutiny: an all-cash $1.8bn outlay equivalent to 2.7 trillion Korean won for a company that competes in capital-intensive biologics manufacturing raises leverage and ROE questions. Investors will focus on whether Samsung Biologics can generate peptide revenue at a rate that justifies the acquisition multiple before its biologics peers close the GLP-1 capacity gap organically, since Lonza and Wuxi Biologics have both announced capacity expansions in the past 18 months.